Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade

Immune checkpoint inhibitors have demonstrated broad single-agent antitumor activity and a favorable safety profile that render them attractive agents to combine with other systemic anticancer therapies. Pancreatic cancer has been fairly resistant to monotherapy blockade of programmed cell death pro...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Transl Med
Egile Nagusiak: Gong, Jun, Hendifar, Andrew, Tuli, Richard, Chuang, Jeremy, Cho, May, Chung, Vincent, Li, Daneng, Salgia, Ravi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Berlin Heidelberg 2018
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6174117/
https://ncbi.nlm.nih.gov/pubmed/30294755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40169-018-0210-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak